| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 961 | 2018 |
| Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma LH Sehn, AF Herrera, CR Flowers, MK Kamdar, A McMillan, M Hertzberg, ... Journal of Clinical Oncology 38 (2), 155, 2020 | 700 | 2020 |
| Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ... Journal of the National Cancer Institute 103 (7), 553-561, 2011 | 523 | 2011 |
| Phase I clinical trial of iv ascorbic acid in advanced malignancy LJ Hoffer, M Levine, S Assouline, D Melnychuk, SJ Padayatty, K Rosadiuk, ... Annals of Oncology 19 (11), 1969-1974, 2008 | 484 | 2008 |
| Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ... The Lancet Oncology 21 (11), 1433-1442, 2020 | 417 | 2020 |
| Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial S Stilgenbauer, B Eichhorst, J Schetelig, P Hillmen, JF Seymour, S Coutre, ... Journal of Clinical Oncology 36 (19), 1973-1980, 2018 | 346 | 2018 |
| Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia M Andreeff, KR Kelly, K Yee, S Assouline, R Strair, L Popplewell, ... Clinical Cancer Research 22 (4), 868-876, 2016 | 339 | 2016 |
| Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin S Assouline, B Culjkovic, E Cocolakis, C Rousseau, N Beslu, A Amri, ... Blood 114 (2), 257-260, 2009 | 339 | 2009 |
| Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study SM Ansell, MC Minnema, P Johnson, JM Timmerman, P Armand, ... Journal of Clinical Oncology 37 (6), 481, 2019 | 337 | 2019 |
| Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a … MCA Palanca-Wessels, M Czuczman, G Salles, S Assouline, LH Sehn, ... The Lancet Oncology 16 (6), 704-715, 2015 | 324 | 2015 |
| Systemic cancer therapy: achievements and challenges that lie ahead MO Palumbo, P Kavan, WH Miller Jr, L Panasci, S Assouline, N Johnson, ... Frontiers in pharmacology 4, 57, 2013 | 295 | 2013 |
| Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia G Garcia-Manero, S Assouline, J Cortes, Z Estrov, H Kantarjian, H Yang, ... Blood, The Journal of the American Society of Hematology 112 (4), 981-989, 2008 | 293 | 2008 |
| Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial JH Lipton, C Chuah, A Guerci-Bresler, G Rosti, D Simpson, S Assouline, ... The Lancet Oncology 17 (5), 612-621, 2016 | 269 | 2016 |
| Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, ... Annals of Oncology 28 (9), 2169-2178, 2017 | 261 | 2017 |
| DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma IW Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, J Mayer, ... Journal of Clinical Oncology 37 (11), 912-+, 2019 | 258 | 2019 |
| Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) F Morschhauser, IW Flinn, R Advani, LH Sehn, C Diefenbach, K Kolibaba, ... The Lancet Haematology 6 (5), e254-e265, 2019 | 236 | 2019 |
| Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study S Mori, E Vagge, P Le Coutre, E Abruzzese, B Martino, E Pungolino, ... American journal of hematology 90 (10), 910-914, 2015 | 234 | 2015 |
| Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study LE Budde, S Assouline, LH Sehn, SJ Schuster, SS Yoon, DH Yoon, ... Journal of Clinical Oncology 40 (5), 481-491, 2022 | 229 | 2022 |
| Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas RD Morin, S Assouline, M Alcaide, A Mohajeri, RL Johnston, L Chong, ... Clinical cancer research 22 (9), 2290-2300, 2016 | 228 | 2016 |
| Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study LE Budde, LH Sehn, M Matasar, SJ Schuster, S Assouline, P Giri, ... The Lancet Oncology 23 (8), 1055-1065, 2022 | 208 | 2022 |
